<?xml version='1.0' encoding='UTF-8'?>
<DOC><DOCNO>WSJ910709-0043</DOCNO><DOCID>910709-0043.</DOCID><HL>   Technology Brief -- Genetics Institute Inc.:   Biotechnology Firm Expects   To Post 2nd-Period Loss</HL><DATE>07/09/91</DATE><SO>WALL STREET JOURNAL (J), PAGE C21</SO><CO>   BAX GENI</CO><MS>CONSUMER NON-CYCLICAL (NCY)TECHNOLOGY (TEC)</MS><IN>DOW JONES INTERVIEW (CEO)MEDICAL SUPPLIES, EYEGLASS MANUFACTURERS (MDS)MEDICAL AND BIOTECHNOLOGY, GENETIC RESEARCH, PROSTHETICS (MTC)</IN><NS>EXCLUSIVE INTERVIEW WITH CHIEF EXECUTIVES (CEO)</NS><RE>ILLINOIS (IL)MASSACHUSETTS (MA)NORTH AMERICA (NME)UNITED STATES (US)</RE><LP>   Genetics Institute Inc. expects to report a second-quarternet loss &quot;comparable&quot; to its first-quarter operating loss ofabout $5.2 million, or 36 cents a share, Garen Bohlin,executive vice president, said.   In the year-earlier second quarter ended May 31, theCambridge, Mass., biotechnology concern had a net loss of$7.9 million, or 64 cents a share. The company expects toreport that revenue rose more than 50% to about $14 millionfrom $9.2 million a year ago, Mr. Bohlin said.</LP><TEXT>   Genetics Institute &quot;clearly expects to operate profitablyin the third and fourth quarters&quot; of fiscal 1991, based onsharply rising revenue, the executive said. Revenue for thefiscal year is projected to be &quot;roughly double&quot; fiscal 1990revenue of $40.4 million, he said.   The expected revenue growth reflects royalties from salesof the anti-anemia drug erythropoeitin, or EPO, in Europe andJapan; manufacturing revenue for Recombinate, anantihemophiliac drug licensed to Baxter Healthcare Corp. thatis expected to be approved for U.S. marketing by early 1992;and &quot;substantial research and development revenues,&quot; Mr.Bohlin said in an interview.</TEXT></DOC>